Treatment preferences of adolescent patients with asthma
The study objective was to assess whether asthmatic adolescents who were regular users of inhaled corticosteroids preferred treatment with zafirlukast tablets or inhaled beclomethasone dipropionate (BDP), and, secondarily, to assess adolescents’ inhaler technique and their opinions about treatment....
Gespeichert in:
| Veröffentlicht in: | Pediatric allergy and immunology 2000-02, Vol.11 (1), p.49-55 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 49 |
| container_title | Pediatric allergy and immunology |
| container_volume | 11 |
| creator | Weinberg, Eugene G. Naya, Ian |
| description | The study objective was to assess whether asthmatic adolescents who were regular users of inhaled corticosteroids preferred treatment with zafirlukast tablets or inhaled beclomethasone dipropionate (BDP), and, secondarily, to assess adolescents’ inhaler technique and their opinions about treatment. An open‐label, randomized, two‐period, cross‐over study was conducted in 18 centres (primary care to specialist asthma centres) in South Africa, the UK, Finland and the Czech Republic. One hundred and thirty‐two adolescents aged 12–17 years with asthma for at least 1 year and FEV1 ≥ 75% of predicted, treated with short‐acting bronchodilators and inhaled corticosteroids, entered the study. Patients received oral zafirlukast tablets (Accolate™) 20 mg bd or inhaled BDP 100 or 200 µg bd, provided by a standard pressurized metered‐dose inhaler, for 4 weeks each. One questionnaire was used to determine preference (the primary outcome measure) and a second questionnaire was used to determine patients’ likes and dislikes of treatment. Investigators also scored inhaler technique. Of 113 adolescents, 79 (70%) preferred zafirlukast compared with 31 (27%) who preferred the BDP inhaler (p |
| doi_str_mv | 10.1034/j.1399-3038.2000.00043.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71029101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71029101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4313-74f1a2c7091d779353fcc9c23f1b2486798021e64af3ebd3e3edfcf1e905cc03</originalsourceid><addsrcrecordid>eNqNkMFu2zAMhoVhxZp2e4XCh2I3e6RpWxawS1FsSbGi2yHYjoIiU6hTO04lB03fvkoddDvuIFAAv1-kPiEShAyBii_rDEmplIDqLAeALJ6Csv07MXtrvBczUFCmFZbyVJyFsAZASRV-EKcIsqollTNRLz2bsefNmGw9O_a8sRySwSWmGToO9rVjxjbWkDy1431iwnjfm4_ixJku8KdjPRfL79-W14v09uf85vrqNrUFIaWycGhyK0FhI6Wikpy1yubkcJUXdSVVDTlyVRhHvGqIiRtnHXJc3Vqgc_F5enbrh8cdh1H3bVyq68yGh13QEiFXCBjBegKtH0KIX9Fb3_bGP2sEfZCm1_rgRh_c6IM0_SpN72P04jhjt-q5-Sc4WYrA5REwwZrOebOxbfjLEeRUyYh9nbCntuPn_56vf13dxEuMp1O8DSPv3-LGP-j4uCz1n7u5_i1_zBcLRZroBYnOldE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71029101</pqid></control><display><type>article</type><title>Treatment preferences of adolescent patients with asthma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Weinberg, Eugene G. ; Naya, Ian</creator><creatorcontrib>Weinberg, Eugene G. ; Naya, Ian</creatorcontrib><description>The study objective was to assess whether asthmatic adolescents who were regular users of inhaled corticosteroids preferred treatment with zafirlukast tablets or inhaled beclomethasone dipropionate (BDP), and, secondarily, to assess adolescents’ inhaler technique and their opinions about treatment. An open‐label, randomized, two‐period, cross‐over study was conducted in 18 centres (primary care to specialist asthma centres) in South Africa, the UK, Finland and the Czech Republic. One hundred and thirty‐two adolescents aged 12–17 years with asthma for at least 1 year and FEV1 ≥ 75% of predicted, treated with short‐acting bronchodilators and inhaled corticosteroids, entered the study. Patients received oral zafirlukast tablets (Accolate™) 20 mg bd or inhaled BDP 100 or 200 µg bd, provided by a standard pressurized metered‐dose inhaler, for 4 weeks each. One questionnaire was used to determine preference (the primary outcome measure) and a second questionnaire was used to determine patients’ likes and dislikes of treatment. Investigators also scored inhaler technique. Of 113 adolescents, 79 (70%) preferred zafirlukast compared with 31 (27%) who preferred the BDP inhaler (p < 0.001); three had no preference. Only 35 (29%) of 122 adolescents could use their inhaler correctly at study entry. Seventy‐six patients (65%) rated zafirlukast tablets as ‘very easy’ to use, compared with 35 (30%) for the BDP inhaler. Both treatments were well tolerated. This study shows that asthmatic adolescents prefer zafirlukast tablets by a ratio of 2.6:1 over inhaled BDP, and these results may have implications for improving adolescent patient compliance with asthma therapy.</description><identifier>ISSN: 0905-6157</identifier><identifier>EISSN: 1399-3038</identifier><identifier>DOI: 10.1034/j.1399-3038.2000.00043.x</identifier><identifier>PMID: 10768735</identifier><language>eng</language><publisher>Copenhagen, Denmark: Munksgaard International Publishers</publisher><subject>Administration, Oral ; Adolescent ; Anti-Asthmatic Agents - administration & dosage ; Anti-Asthmatic Agents - therapeutic use ; asthma ; Asthma - drug therapy ; beclomethasone ; Beclomethasone - administration & dosage ; Beclomethasone - therapeutic use ; Biological and medical sciences ; Child ; corticosteroid inhaler ; Cross-Over Studies ; Female ; Humans ; leukotriene receptor antagonist ; Male ; Medical sciences ; Nebulizers and Vaporizers ; oral therapy ; Patient Compliance ; Patient Satisfaction ; Pharmacology. Drug treatments ; preference ; Respiratory system ; Surveys and Questionnaires ; Tablets ; Tosyl Compounds - administration & dosage ; Tosyl Compounds - therapeutic use ; zafirlukast</subject><ispartof>Pediatric allergy and immunology, 2000-02, Vol.11 (1), p.49-55</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4313-74f1a2c7091d779353fcc9c23f1b2486798021e64af3ebd3e3edfcf1e905cc03</citedby><cites>FETCH-LOGICAL-c4313-74f1a2c7091d779353fcc9c23f1b2486798021e64af3ebd3e3edfcf1e905cc03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1034%2Fj.1399-3038.2000.00043.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1302367$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10768735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weinberg, Eugene G.</creatorcontrib><creatorcontrib>Naya, Ian</creatorcontrib><title>Treatment preferences of adolescent patients with asthma</title><title>Pediatric allergy and immunology</title><addtitle>Pediatr Allergy Immunol</addtitle><description>The study objective was to assess whether asthmatic adolescents who were regular users of inhaled corticosteroids preferred treatment with zafirlukast tablets or inhaled beclomethasone dipropionate (BDP), and, secondarily, to assess adolescents’ inhaler technique and their opinions about treatment. An open‐label, randomized, two‐period, cross‐over study was conducted in 18 centres (primary care to specialist asthma centres) in South Africa, the UK, Finland and the Czech Republic. One hundred and thirty‐two adolescents aged 12–17 years with asthma for at least 1 year and FEV1 ≥ 75% of predicted, treated with short‐acting bronchodilators and inhaled corticosteroids, entered the study. Patients received oral zafirlukast tablets (Accolate™) 20 mg bd or inhaled BDP 100 or 200 µg bd, provided by a standard pressurized metered‐dose inhaler, for 4 weeks each. One questionnaire was used to determine preference (the primary outcome measure) and a second questionnaire was used to determine patients’ likes and dislikes of treatment. Investigators also scored inhaler technique. Of 113 adolescents, 79 (70%) preferred zafirlukast compared with 31 (27%) who preferred the BDP inhaler (p < 0.001); three had no preference. Only 35 (29%) of 122 adolescents could use their inhaler correctly at study entry. Seventy‐six patients (65%) rated zafirlukast tablets as ‘very easy’ to use, compared with 35 (30%) for the BDP inhaler. Both treatments were well tolerated. This study shows that asthmatic adolescents prefer zafirlukast tablets by a ratio of 2.6:1 over inhaled BDP, and these results may have implications for improving adolescent patient compliance with asthma therapy.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>asthma</subject><subject>Asthma - drug therapy</subject><subject>beclomethasone</subject><subject>Beclomethasone - administration & dosage</subject><subject>Beclomethasone - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>corticosteroid inhaler</subject><subject>Cross-Over Studies</subject><subject>Female</subject><subject>Humans</subject><subject>leukotriene receptor antagonist</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nebulizers and Vaporizers</subject><subject>oral therapy</subject><subject>Patient Compliance</subject><subject>Patient Satisfaction</subject><subject>Pharmacology. Drug treatments</subject><subject>preference</subject><subject>Respiratory system</subject><subject>Surveys and Questionnaires</subject><subject>Tablets</subject><subject>Tosyl Compounds - administration & dosage</subject><subject>Tosyl Compounds - therapeutic use</subject><subject>zafirlukast</subject><issn>0905-6157</issn><issn>1399-3038</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMFu2zAMhoVhxZp2e4XCh2I3e6RpWxawS1FsSbGi2yHYjoIiU6hTO04lB03fvkoddDvuIFAAv1-kPiEShAyBii_rDEmplIDqLAeALJ6Csv07MXtrvBczUFCmFZbyVJyFsAZASRV-EKcIsqollTNRLz2bsefNmGw9O_a8sRySwSWmGToO9rVjxjbWkDy1431iwnjfm4_ixJku8KdjPRfL79-W14v09uf85vrqNrUFIaWycGhyK0FhI6Wikpy1yubkcJUXdSVVDTlyVRhHvGqIiRtnHXJc3Vqgc_F5enbrh8cdh1H3bVyq68yGh13QEiFXCBjBegKtH0KIX9Fb3_bGP2sEfZCm1_rgRh_c6IM0_SpN72P04jhjt-q5-Sc4WYrA5REwwZrOebOxbfjLEeRUyYh9nbCntuPn_56vf13dxEuMp1O8DSPv3-LGP-j4uCz1n7u5_i1_zBcLRZroBYnOldE</recordid><startdate>200002</startdate><enddate>200002</enddate><creator>Weinberg, Eugene G.</creator><creator>Naya, Ian</creator><general>Munksgaard International Publishers</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200002</creationdate><title>Treatment preferences of adolescent patients with asthma</title><author>Weinberg, Eugene G. ; Naya, Ian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4313-74f1a2c7091d779353fcc9c23f1b2486798021e64af3ebd3e3edfcf1e905cc03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>asthma</topic><topic>Asthma - drug therapy</topic><topic>beclomethasone</topic><topic>Beclomethasone - administration & dosage</topic><topic>Beclomethasone - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>corticosteroid inhaler</topic><topic>Cross-Over Studies</topic><topic>Female</topic><topic>Humans</topic><topic>leukotriene receptor antagonist</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nebulizers and Vaporizers</topic><topic>oral therapy</topic><topic>Patient Compliance</topic><topic>Patient Satisfaction</topic><topic>Pharmacology. Drug treatments</topic><topic>preference</topic><topic>Respiratory system</topic><topic>Surveys and Questionnaires</topic><topic>Tablets</topic><topic>Tosyl Compounds - administration & dosage</topic><topic>Tosyl Compounds - therapeutic use</topic><topic>zafirlukast</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weinberg, Eugene G.</creatorcontrib><creatorcontrib>Naya, Ian</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric allergy and immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weinberg, Eugene G.</au><au>Naya, Ian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment preferences of adolescent patients with asthma</atitle><jtitle>Pediatric allergy and immunology</jtitle><addtitle>Pediatr Allergy Immunol</addtitle><date>2000-02</date><risdate>2000</risdate><volume>11</volume><issue>1</issue><spage>49</spage><epage>55</epage><pages>49-55</pages><issn>0905-6157</issn><eissn>1399-3038</eissn><abstract>The study objective was to assess whether asthmatic adolescents who were regular users of inhaled corticosteroids preferred treatment with zafirlukast tablets or inhaled beclomethasone dipropionate (BDP), and, secondarily, to assess adolescents’ inhaler technique and their opinions about treatment. An open‐label, randomized, two‐period, cross‐over study was conducted in 18 centres (primary care to specialist asthma centres) in South Africa, the UK, Finland and the Czech Republic. One hundred and thirty‐two adolescents aged 12–17 years with asthma for at least 1 year and FEV1 ≥ 75% of predicted, treated with short‐acting bronchodilators and inhaled corticosteroids, entered the study. Patients received oral zafirlukast tablets (Accolate™) 20 mg bd or inhaled BDP 100 or 200 µg bd, provided by a standard pressurized metered‐dose inhaler, for 4 weeks each. One questionnaire was used to determine preference (the primary outcome measure) and a second questionnaire was used to determine patients’ likes and dislikes of treatment. Investigators also scored inhaler technique. Of 113 adolescents, 79 (70%) preferred zafirlukast compared with 31 (27%) who preferred the BDP inhaler (p < 0.001); three had no preference. Only 35 (29%) of 122 adolescents could use their inhaler correctly at study entry. Seventy‐six patients (65%) rated zafirlukast tablets as ‘very easy’ to use, compared with 35 (30%) for the BDP inhaler. Both treatments were well tolerated. This study shows that asthmatic adolescents prefer zafirlukast tablets by a ratio of 2.6:1 over inhaled BDP, and these results may have implications for improving adolescent patient compliance with asthma therapy.</abstract><cop>Copenhagen, Denmark</cop><pub>Munksgaard International Publishers</pub><pmid>10768735</pmid><doi>10.1034/j.1399-3038.2000.00043.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0905-6157 |
| ispartof | Pediatric allergy and immunology, 2000-02, Vol.11 (1), p.49-55 |
| issn | 0905-6157 1399-3038 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71029101 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Adolescent Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - therapeutic use asthma Asthma - drug therapy beclomethasone Beclomethasone - administration & dosage Beclomethasone - therapeutic use Biological and medical sciences Child corticosteroid inhaler Cross-Over Studies Female Humans leukotriene receptor antagonist Male Medical sciences Nebulizers and Vaporizers oral therapy Patient Compliance Patient Satisfaction Pharmacology. Drug treatments preference Respiratory system Surveys and Questionnaires Tablets Tosyl Compounds - administration & dosage Tosyl Compounds - therapeutic use zafirlukast |
| title | Treatment preferences of adolescent patients with asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A05%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20preferences%20of%20adolescent%20patients%20with%20asthma&rft.jtitle=Pediatric%20allergy%20and%20immunology&rft.au=Weinberg,%20Eugene%20G.&rft.date=2000-02&rft.volume=11&rft.issue=1&rft.spage=49&rft.epage=55&rft.pages=49-55&rft.issn=0905-6157&rft.eissn=1399-3038&rft_id=info:doi/10.1034/j.1399-3038.2000.00043.x&rft_dat=%3Cproquest_cross%3E71029101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71029101&rft_id=info:pmid/10768735&rfr_iscdi=true |